ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study

Pu, Xingxiang; Wang, QianZhi; Liu, Liyu; Chen, Bolin; Li, Kang; Zhou, Yu; Sheng, Zengmei; Liu, Ping; Tang, Yucheng; Xu, Li; Li, Jia; Kong, Yi; Xu, Fang; Xu, Yan; Wu, Lin*南方医科大学
Cancer Medicine2023-4DOI: 10.1002/cam4.5526
3被引4阅读
引用收藏
分享

摘要

BackgroundClinical evidence of immune checkpoint inhibitors combined with antiangiogenic drugs in patients with advanced non-small cell lung cancer (NSCLC) was limited. Recombinant human endostatin (rh-endostatin), an antiangiogenic drug, and camrelizumab, an anti-PD-1 antibody, have been approved for the treatment of advanced NSCLC in China. This study aimed to investigate the efficacy and safety of rh-endostatin plus camrelizumab and chemotherapy in the treatment of advanced NSCLC. MethodsEligible patients were enrolled and received camrelizumab (200 mg, day 1) every 3 weeks and continuous intravenous infusion of rh-endostatin (70 mg/day, days 1-3) and cisplatin combined with pemetrexed (for adenocarcinoma) or paclitaxel (for NSCLC other than adenocarcinoma) every 3 weeks. Primary endpoint was progression-free survival (PFS). Secondary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety profiles. ResultsOverall, 27 patients were included, and 25 patients were eligible for efficacy evaluation. For these 25 patients, ORR was 48.15% (13/27) and DCR was 85.19% (23/27). With a median follow-up of 10.37 months, the median PFS was 8.9 (95% CI: 4.23-13.57) months. Median OS was not reached. Overall, 96.3% of patients experienced at least one treatment-related adverse event, and grade 3 TRAEs occurred in 9 (33.3%) patients. No unexpected AEs were observed. ConclusionRh-endostatin plus camrelizumab and chemotherapy showed favorable efficacy and safety profile in patients with advanced NSCLC, representing a promising treatment regimen for these patients.

学科与关键词

关键词
anti-angiogenesiscamrelizumabimmune checkpoint inhibitorsnon-small cell lung cancerrecombinant human endostatin
相关
加载中…
  • First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
    Ren, Shengxiang; Wang, Xicheng; Han, Bao-Hui; Pan, Yueyin; Zhao, Jun; Cheng, Yufeng; Hu, Sheng; Liu, Tianshu; Li, Yalun; Cheng, Ying; Feng, Jifeng; Yi, Shanyong; Gu, Shanzhi; Gao, Shegan; Luo, Yongzhong; Liu, Ying; Liu, Caigang; Duan, Huijie; Wang, Shuni; Yang, Xinfeng; Fan, Jia*; Zhou, Caicun*Journal for ImmunoTherapy of Cancer, 2024, 12(2): e007227.
  • Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real- world retrospective observational study (CTONG2004-ADV)
    Xu, Chong-Rui; Chen, Qixun; Zhou, Chengzhi; Wu, Lin; Li, Wen; Zhang, Huizhong; Li, Yongsheng; Xu, Fei; Xiong, Jianping; Wang, Qiming; Zhang, Haibo; Jiang, Yuequan; Yin, Haitao; Wu, Qingchen; Dai, Qiangsheng; Hu, Jian; Chen, Jianhua; Zhang, Jian; Wu, Gang; Yin, Jun; Zhao, Jianfu; Liu, Baogang; Shan, Jianzhen; Sheng, Liming; Chen, Qunqing; Han, Zhengxiang; Shi, Huaqiu; Liu, Yimin; Chen, Jun; Wu, Yi-Long*Translational Lung Cancer Research, 2023, 12(1): 127-+.
  • Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
    Gao, Guanghui; Zhao, Jun; Ren, Shengxiang; Wang, Yina; Chen, Gongyan; Chen, Jianhua; Gu, Kangsheng; Guo, Renhua; Pan, Yueyin; Wang, Quanren; Li, Weixia; Yang, Xinfeng; Zhou, Caicun*Annals of Translational Medicine, 2022, 10(8): 441.被引 11
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Medicine
发表日期
2023-04
卷期
第 12 卷, 第 7 期
页码
7724-7733
DOI
10.1002/cam4.5526
语言
ENGLISH
成果收录
SCIE

作者

  • P

    Pu, Xingxiang (第一作者)

    hunan canc hosp

  • W

    Wang, QianZhi

    hunan canc hosp

查看全部 15 位作者收起作者
  • L

    Liu, Liyu

    hunan canc hosp

  • C

    Chen, Bolin

    hunan canc hosp

  • L

    Li, Kang

    hunan canc hosp

  • Z

    Zhou, Yu

    hunan canc hosp

  • S

    Sheng, Zengmei

  • L

    Liu, Ping

    first hosp changsha

  • T

    Tang, Yucheng

    southern med univ

  • X

    Xu, Li

    hunan canc hosp

  • L

    Li, Jia

    hunan canc hosp

  • K

    Kong, Yi

    hunan canc hosp

  • X

    Xu, Fang

    hunan canc hosp

  • X

    Xu, Yan

    hunan canc hosp

  • W

    Wu, Lin (通讯)

    hunan canc hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417